Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| PD-1 VHH mAb - 01 | PCC | Solid Tumor | Solid tumor |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| SIRPα×PD-1 bsAb | Bispecific antibody | Oncology/Cancer | Advanced solid tumor | Preclinical | Global |
| PD-1×TIGIT BsAb for Advanced solid tumor | Bispecific antibody | Oncology/Cancer | Cancer | Preclinical | Global |
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolgolimab | BCD-100 | Approved | Biocad | Forteca | Russian Federation | Melanoma | Biocad | 2020-04-01 | Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
| Sintilimab | IBI-308 | Approved | Innovent Biologics(Suzhou) Co Ltd | Tyvyt, 达伯舒 | Mainland China | Stomach Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2018-12-24 | Sarcoma; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Neoplasms, Unknown Primary; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Neuroendocrine; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Lung Diseases; Respiratory Tract Diseases; Hodgkin Disease; Nasopharyngeal Neoplasms; Neoplasms; Thoracic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral | Details |
| Pucotenlimab | AK-103; HX-008 | Approved | Taizhou Hanzhong Biomedical Co Ltd, Hanx Biopharmaceutical Co Ltd, Zhongshan Akeso Biopharma Co Ltd, Lepu Biotech Co Ltd | 普佑恒 | Mainland China | Melanoma | Lepu Biotech Co Ltd | 2022-07-19 | Solid tumours; Mismatch Repair Deficient Cancer; Esophageal Neoplasms; Stomach Neoplasms; Thyroid Carcinoma, Anaplastic; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Colorectal Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Penpulimab | AK-105 | Approved | Zhongshan Akeso Biopharma Co Ltd | 安尼可 | Mainland China | Hodgkin Disease | Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd | 2021-08-03 | Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Hodgkin Disease; Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Head and Neck Neoplasms; Liver Neoplasms | Details |
| Cadonilimab | AK-104 | Approved | Zhongshan Akeso Biopharma Co Ltd | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; DNA Repair-Deficiency Disorders; Microsatellite Instability; Lymphoma, T-Cell, Peripheral; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| Zimberelimab | AB-122; GLS-010; WBP-3055 | Approved | Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Biologics (Shanghai) Co Ltd | 誉妥 | Mainland China | Hodgkin Disease | Guangzhou Yuheng Biotechnology Co Ltd | 2021-08-25 | Urinary Bladder Neoplasms; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms | Details |
| Toripalimab | JS-001sc; TAB-001; JS-001; SO-001 | Approved | Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd | 拓益 | Mainland China | Carcinoma, Non-Small-Cell Lung | Shanghai Junshi Biosciences Co Ltd | 2018-12-17 | Lymphoma; Urinary Bladder Neoplasms; Rejection of organ transplantation; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Urologic Neoplasms; Colorectal Neoplasms; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Epstein-Barr Virus Infections; Laryngeal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Stomach Neoplasms; Solid tumours; Colorectal Neoplasms, Hereditary Nonpolyposis; Head and Neck Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Kidney Neoplasms; Pain; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Neoplasms; Nasopharyngeal Diseases; Hypopharyngeal Neoplasms | Details |
| Nivolumab | MDX-1106; ONO-4538; ono-0123; BMS-936558; BMS-936558-01 | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | Opdivo, 欧狄沃 | Japan | Carcinoma, Transitional Cell | Ono Pharmaceutical Co Ltd | 2014-07-04 | Liver Neoplasms; Leiomyosarcoma; Solid tumours; Bone Marrow Neoplasms; Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Acquired Immunodeficiency Syndrome; Tobacco Smoking; Head and Neck Neoplasms; Biliary Tract Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ependymoma; Medulloblastoma; Hematopoietic stem cell transplantation (HSCT); Kidney Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; HIV Infections; Esophageal Neoplasms; Stomach Neoplasms; Polycythemia Vera; Carcinoma, Renal Cell; Giant Cell Arteritis; Squamous Cell Carcinoma of Head and Neck; Leukoplakia, Oral; Mismatch Repair Deficient Cancer; Leukemia, Lymphoid; Rectal Neoplasms; Anus Neoplasms; Inflammatory Bowel Diseases; Dermatomyositis; Thoracic Neoplasms; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; HTLV-I Infections; Enteropathy-Associated T-Cell Lymphoma; Hodgkin Disease; Myelodysplastic Syndromes; Adrenal Cortex Neoplasms; Glioblastoma; Arthritis, Rh | Details |
| Cemiplimab | SAR-439684; REGN-2810 | Approved | Regeneron Pharmaceuticals Inc | Libtayo | EU | Uterine Cervical Neoplasms | Regeneron Ireland Designated Activity Company | 2018-09-28 | Sarcoma; Mycosis Fungoides; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Mouth Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Diffuse Intrinsic Pontine Glioma; Peritoneal Neoplasms; Hepatitis B; Prostatic Neoplasms; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Skin Neoplasms; Carcinoma, Transitional Cell; Papillomavirus Infections; Hodgkin Disease; Neoplasms; Carcinoma, Merkel Cell; Hemangiosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; HIV Infections; Ovarian Neoplasms | Details |
| Tislelizumab | BGB-A317; VDT-482 | Approved | Beigene Ltd | 百泽安 | Mainland China | Nasopharyngeal Carcinoma | Beigene Guangzhou Biologics Manufacturing Co Ltd | 2019-12-26 | Lymphoma, T-Cell, Cutaneous; Digestive System Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Large-Cell, Anaplastic; Urinary Bladder Neoplasms; Lymphoma, T-Cell; Lymphoma; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Rectal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia; Liver Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Solid tumours; Anus Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Microsatellite instability-high cancer | Details |
| Camrelizumab | SHR-1210; INCSHR-1210; HR-301210 | Approved | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | AiRuiKa, 艾瑞卡, 艾立妥 | Mainland China | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2019-05-29 | Carcinoma, Squamous Cell; Cholangiocarcinoma; Lymphoma, Extranodal NK-T-Cell; Respiratory Tract Neoplasms; Breast Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Lung Neoplasms; Endometrial Neoplasms; Nasopharyngeal Carcinoma; Paranasal Sinus Neoplasms; Esophageal adenocarcinoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Melanoma; Uterine Cervical Neoplasms; Esophageal Diseases; Triple Negative Breast Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic; Hemorrhagic Fever, Ebola; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Bronchial Neoplasms; Thoracic Neoplasms; Hodgkin Disease; Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hypopharyngeal Neoplasms; Respiratory Tract Diseases; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Urinary Bladder | Details |
| Dostarlimab | WBP-285; TSR-042; ANB-011 | Approved | Anaptysbio Inc | JEMPERLI | United States | Solid tumours | Glaxosmithkline Llc | 2021-04-21 | Sarcoma, Clear Cell; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Solid tumours; Breast Neoplasms; Gestational Trophoblastic Disease; Mesothelioma; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Rectal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
| Pembrolizumab | SCH-900475; h409A11; MK-3475 | Approved | Merck & Co Inc | 可瑞达, Keytruda | Mainland China | Triple Negative Breast Neoplasms | Moshadong R & D (China) Co Ltd | 2014-09-04 | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Ependymoma; Lymphoma, B-Cell; Solitary Fibrous Tumor, Pleural; Kidney Neoplasms; Medulloblastoma; Lymphoma, B-Cell, Marginal Zone; Biliary Tract Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Neoplasm Recurrence, Local; Lymphoma, T-Cell, Peripheral; Erythema; Neoplasm, Residual; HIV Infections; Bone metastases; Protein Deficiency; Intestinal Neoplasms; Leiomyosarcoma; Ovarian germ cell tumor; Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Spinal Cord Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Anus Neoplasms; Carcinoma, Merkel Cell; Vaginal Diseases; Carcinoid Tumor; Polycythemia Vera; Mismatch Repair Deficient Cancer; Vaginitis; Cystadenocarcinoma, Serous; Genital Neoplasms, Male; Pheochromocytoma; Rectal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Hodgkin Disease; | Details |
| Nivolumab/Relatlimab | BMS-986213; BMS-936558/BMS-986016 | Approved | Bristol-Myers Squibb Company | OPDUALAG | EU | Melanoma | Bristol-Myers Squibb Pharma Eeig | 2022-03-18 | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| Serplulimab | HLX-10 | Approved | Shanghai Henlius Biotech Co Ltd | 汉斯状 | Mainland China | Microsatellite instability-high cancer | Shanghai Henlius Biopharmaceuticals Co Ltd | 2022-03-22 | Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Microsatellite Instability; Microsatellite instability-high cancer; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Carcinoma; Liver Neoplasms; Head and Neck Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| 89Zr-N-sucDf-pembrolizumab | Phase 1 Clinical | Merck & Co Inc, Umcg The University Medical Center Groningen | Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
| PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
| STW204 | STW-204; AI025; AI-025 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Solid tumours; Neoplasms | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxi Weiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
| INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
| Treprilimab | Clinical | Sun Yat-Sen University | Oropharyngeal Neoplasms | Details | |
| ABBV-1882 | ABBV-1882 | Phase 1 Clinical | Abbvie Inc | HIV Infections | Details |
| Pembrolizumab biosimilar (biocad) | BCD-201 | Phase 1 Clinical | Biocad | Solid tumours | Details |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | Neoplasms | Details | |
| Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) | Phase 2 Clinical | Carcinoma, Ovarian Epithelial; Bile Duct Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details | ||
| SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| HerinCAR-PD1 | Phase 2 Clinical | Ningbo Cancer Hospital | Solid tumours | Details | |
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Phase 2 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details | |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Stomach Neoplasms; Esophageal adenocarcinoma | Details | |
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
| GNR-051 | GNR-051 | Generium Pharmaceuticals | Details | ||
| PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Details |
| CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
| JS-201 | JS-201 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Neoplasms | Details |
| LBL-015 | LBL-015 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Solid tumours | Details |
| SHR-1901 | SHR-1901 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| SSI-361 | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Neoplasms | Details |
| CA-170 | CA-170; AUPM-170 | Aurigene | Details | ||
| TQB-2868 | TQB-2868 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| Rosnilimab | ANB-030 | Anaptysbio Inc | Alopecia Areata | Details | |
| Peramprizumab | Phase 2 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
| Sym-024 | Sym-024; S-95024 | Symphogen A/S | Details | ||
| BI-1387446 | C.H. Boehringer Sohn Ag & Co. Kg | Details | |||
| BCD-217 | BCD-217 | Biocad | Details | ||
| BAT-1308 | BAT-1308 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| CMAB-819 | CMAB8-19 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Programmed cell death 1 antibody (Sun Yat-sen University) | Sun Yat-Sen University | Details | |||
| Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) | Phase 1 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
| IAP-0971 | IAP-0971 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| ZG-005 | ZG-005 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
| HX-009 | HX-009 | Phase 2 Clinical | Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
| TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Lymphoma | Details |
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Hematologic Neoplasms; Colorectal Neoplasms | Details | |
| CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio Inc | Autoimmune Diseases; Psoriasis | Details |
| SI-B003 | SI-B003 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
| Sym-021 | Sym-021 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
| IMU-201 | IMU-201 | Phase 1 Clinical | Imugene Ltd | Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) | Phase 2 Clinical | Xinqiao Hospital, Army Medical University | Squamous Cell Carcinoma of Head and Neck | Details | |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Pimivalimab | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AZD-2936 | AZD-2936 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung | Details |
| BA1104 | LY-01015; BA-1104 | Phase 1 Clinical | Luye Pharma Group Ltd | Liver Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Neoplasms | Details |
| SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| Latikafusp | AMG-256 | Phase 1 Clinical | Amgen Inc | Solid tumours; Neoplasms | Details |
| RO-7121661 | RG-7769; RO-7121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Sumgen) | SG-001; SYSA1802 | Phase 2 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 2 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases | Details | |
| Rulonilimab | F-520 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours; Lymphoma, T-Cell, Peripheral; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus Nv | Psoriasis; Lymphoma, T-Cell | Details |
| IBI-363 | IBI-363 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| MK-3475A | MK-3475A | Phase 1 Clinical | Merck Sharp & Dohme Corp | Solid tumours | Details |
| Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics Inc | Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| Peresolimab | LY-3462817 | Phase 2 Clinical | Eli Lilly And Company | Autoimmune Diseases; Arthritis, Rheumatoid; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis | Details |
| Finotonlimab | SCT-I10A | Phase 3 Clinical | SinoCelltech Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangsheng Tang Co Ltd, Xiamen University | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Brain metastases; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details | |
| Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms | Details |
| AK-129 | AK-129 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Neoplasms | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours; Neoplasms | Details |
| Budigalimab | ABBV-181 | Phase 2 Clinical | Abbvie Inc | Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| QL1604 | QL1604; QL-1604 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
| Taminadenant | NIR-178; PBF-509 | Phase 2 Clinical | Palobiofarma Sl | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| PE0105 | PE-0105 | Phase 1 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Neoplasms | Details |
| MEDI-5752 | MEDI-5752 | Phase 1 Clinical | Medimmune Llc | Solid tumours; Carcinoma, Renal Cell | Details |
| RO-7247669 | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Liver Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| T3011 | MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
| PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 2 Clinical | Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital | Esophageal Neoplasms | Details | |
| Zeluvalimab | AMG-404 | Phase 2 Clinical | Amgen Inc | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Vudalimab | XmAb-20717; XmAb-717 | Phase 2 Clinical | Xencor Inc | Carcinoma, Neuroendocrine; Vulvar Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours | Details |
| Mavezelimab/Pembrolizumab | MK-4280A; MK-4820A | Phase 3 Clinical | Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
| Iparomlimab/Tuvonralimab | QL-1706; PSB-205; PBS-103/PBS-105 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Spartalizumab | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Carcinoma, Pancreatic Ductal; Chordoma; Urinary Bladder Neoplasms; Uveal melanoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Primary Myelofibrosis; Gastrointestinal Stromal Tumors; Bone Marrow Diseases; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Uterine Neoplasms; Metastatic breast cancer; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Endometrioid; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms | Details |
| TC-510 | TC-510 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Adenocarcinoma | Details |
| Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Ovarian Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
| Carrelizumab | Phase 3 Clinical | Beijing Chest Hospital | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Sasanlimab | PF-06801591; PF-6801591; RN-888 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Cetrelimab | JNJ-63723283; JNJ-3283 | Phase 3 Clinical | Johnson & Johnson | Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell | Details |
| Retifanlimab | INCMGA-0012; INCMGA-00012; MGA-012 | Phase 3 Clinical | Macrogenics Inc | Esophageal adenocarcinoma; Prostatic Neoplasms; Sarcoma; Lymphoma, Follicular; Breast Neoplasms; Astrocytoma; Colorectal Neoplasms; Glioma; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Melanoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Anus Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Oligodendroglioma; Liposarcoma | Details |
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
| INCA-32459 | INCA-32459 | Phase 1 Clinical | Incyte Corp, Merus Nv | Neoplasms | Details |
| Ivonescimab | AK-112 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| LZM-009 | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
| MW-11 | MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Breast Neoplasms | Details |
| Acrixolimab | YBL-006; YBL 006 | Phase 2 Clinical | Y-biologics Inc | Solid tumours; Neoplasms | Details |
| IBI-319 | IBI-319 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
| IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| PH-762 | PH-762 | Phase 1 Clinical | Phio Pharmaceuticals Corp | Breast Neoplasms; Melanoma | Details |
| Pidilizumab | MDV-9300; CT-011 | Phase 2 Clinical | Curetech Ltd | Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| Nofazinlimab | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | 609-A; SSGJ-609A; SSGJ-609-A | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Sarcoma; Breast Neoplasms | Details |
| AZD-7789 | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Hodgkin Disease; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
